Acasti Pharma Inc

For the period ended Mar 31, 2024. Filed Jun 21, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Jun 21, 2024

GRCE$1.87+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ACASTI PHARMA INC.
By:	/s/ Prashant Kohli
Name:	Prashant Kohli
	Title: Chief Executive Officer and
	(Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Brian Davis
Signature	Title	Date
/s/ Prashant Kohli	Chief Executive Officer	June 21, 2024
Prashant Kohli	(Principal Executive Officer)
/s/ Robert DelAversano	Principal Financial Officer	June 21, 2024
Robert DelAversano	(Principal Financial Officer and Principal Accounting Officer)
/s/ Brian Davis	Director	June 21, 2024
/s/Vimal Kavuru	Director	June 21, 2024
Vimal Kavuru
/s/Edward Neugeboren	Director	June 21, 2024
Edward Neugeboren

George Kottayil
/s/George Kottayil	Director	June 21, 2024

For the years ended March 31, 2024 and 2023

Reports of Independent Registered Public Accounting Firms	F-1
Consolidated Balance Sheets	F-3
Consolidated Statements of Operations and Comprehensive Loss	F-4
Consolidated Statements of Shareholders’ Equity	F-5
Consolidated Statements of Cash Flows	F-6
Notes to the Consolidated Financial Statements	F-7

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.